Low-dose-rate Brachytherapy for Patients with Transurethral Resection Before Implantation in Prostate Cancer. Longterm Results

Overview

Journal Int Braz J Urol

Specialty Urology

Date 2016 May 3

PMID 27136466

Citations 3

Authors

Pedro J Prada

Javier Anchuelo

Ana Garcia Blanco

Gema Paya

Juan Cardenal

Enrique Acuna

Maria Ferri

Andres Vazquez

Maite Pacheco

Jesica Sanchez

Affiliations

Soon will be listed here.

Abstract

Objectives: We analyzed the long-term oncologic outcome for patients with prostate cancer and transurethral resection who were treated using low-dose-rate (LDR) prostate brachytherapy.

Methods And Materials: From January 2001 to December 2005, 57 consecutive patients were treated with clinically localized prostate cancer. No patients received external beam radiation. All of them underwent LDR prostate brachytherapy. Biochemical failure was defined according to the "Phoenix consensus". Patients were stratified as low and intermediate risk based on The Memorial Sloan Kettering group definition.

Results: The median follow-up time for these 57 patients was 104 months. The overall survival according to Kaplan-Meier estimates was 88% (±6%) at 5 years and 77% (±6%) at 12 years. The 5 and 10 years for failure in tumour-free survival (TFS) was 96% and respectively (±2%), whereas for biochemical control was 94% and respectively (±3%) at 5 and 10 years, 98% (±1%) of patients being free of local recurrence. A patient reported incontinence after treatment (1.7%). The chronic genitourinary complains grade I were 7% and grade II, 10%. At six months 94% of patients reported no change in bowel function.

Conclusions: The excellent long-term results and low morbidity presented, as well as the many advantages of prostate brachytherapy over other treatments, demonstrates that brachytherapy is an effective treatment for patients with transurethral resection and clinical organ-confined prostate cancer.

Citing Articles

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer.

Blacksburg S, Fuller D, Haas J Front Oncol. 2021; 10:627686.

PMID: 33384965 PMC: 7770153. DOI: 10.3389/fonc.2020.627686.

A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial.

Salembier C, Henry A, Pieters B, Hoskin P J Contemp Brachytherapy. 2020; 12(1):1-5.

PMID: 32190063 PMC: 7073343. DOI: 10.5114/jcb.2020.92913.

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes.

Chao M, Spencer S, Guerrieri M, Ding W, Goharian M, Ho H J Contemp Brachytherapy. 2018; 10(2):155-161.

PMID: 29789764 PMC: 5961530. DOI: 10.5114/jcb.2018.75600.

References

Zelefsky M, Hollister T, Raben A, Matthews S, Wallner K . Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000; 47(5):1261-6. DOI: 10.1016/s0360-3016(00)00550-2. View

Zelefsky M, Leibel S, Gaudin P, Kutcher G, Fleshner N, Venkatramen E . Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998; 41(3):491-500. DOI: 10.1016/s0360-3016(98)00091-1. View

Moran B, Stutz M, Gurel M . Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. Int J Radiat Oncol Biol Phys. 2004; 59(2):392-6. DOI: 10.1016/j.ijrobp.2003.10.013. View

Joseph J, Al-Qaisieh B, Ash D, Bottomley D, Carey B . Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy. BJU Int. 2004; 94(9):1235-8. DOI: 10.1111/j.1464-410X.2004.05149.x. View

Salembier C, Rijnders A, Henry A, Niehoff P, Siebert F, Hoskin P . Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection. J Contemp Brachytherapy. 2013; 5(2):63-9. PMC: 3708148. DOI: 10.5114/jcb.2013.36174. View

Grado G, Larson T, Balch C, Grado M, Collins J, Kriegshauser J . Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys. 1998; 42(2):289-98. DOI: 10.1016/s0360-3016(98)00209-0. View

Prada P, Gonzalez H, Menendez C, Llaneza A, Fernandez J, Santamarta E . Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy. 2009; 8(2):210-217. DOI: 10.1016/j.brachy.2008.11.010. View

Blasko J, RAGDE H, Grimm P . Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl. 1991; 137:113-8. View

Claros D, Correia J, Ferreira L, Vaz F . [Retrospective evaluation of urinary continence in patients submitted to brachytherapy after transurethral resection of the prostate gland]. Actas Urol Esp. 2009; 33(4):356-60. DOI: 10.1016/s0210-4806(09)74160-9. View

10.

Prada P, Juan G, Gonzalez-Suarez H, Fernandez J, Jimenez I, Amon J . Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants. BJU Int. 2010; 106(1):32-6. DOI: 10.1111/j.1464-410X.2009.09096.x. View

11.

Bice Jr W, Prestidge B, Prete J, DuBois D . Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using 125I. American Association of Physicists in Medicine. Int J Radiat Oncol Biol Phys. 1998; 40(5):1237-41. DOI: 10.1016/s0360-3016(97)00949-8. View

12.

Gerber G, Thisted R, Chodak G, Schroder F, FROHMULLER H, Scardino P . Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol. 1997; 32(4):385-90. View

13.

Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley W, Sokol G . Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4):965-74. DOI: 10.1016/j.ijrobp.2006.04.029. View

14.

Prada P, Juan G, Fernandez J, Gonzalez-Suarez H, Martinez A, Gonzalez J . Conformal prostate brachytherapy guided by realtime dynamic dose calculations using permanent 125iodine implants: technical description and preliminary experience. Arch Esp Urol. 2006; 59(9):933-40. DOI: 10.4321/s0004-06142006000900021. View

15.

Talcott J, Clark J, Stark P, Mitchell S . Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol. 2001; 166(2):494-9. View

16.

Pollack A, Zagars G, Smith L, Lee J, Von Eschenbach A, Antolak J . Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000; 18(23):3904-11. DOI: 10.1200/JCO.2000.18.23.3904. View

17.

Foote J, Yun S, Leach G . Postprostatectomy incontinence. Pathophysiology, evaluation, and management. Urol Clin North Am. 1991; 18(2):229-41. View

18.

Stone N, Ratnow E, Stock R . Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Tech Urol. 2000; 6(2):123-7. View

19.

Cesaretti J, Stone N, Stock R . Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis. Int J Radiat Oncol Biol Phys. 2004; 60(2):648-53. DOI: 10.1016/j.ijrobp.2004.05.070. View

20.

Nag S, Ciezki J, Cormack R, Doggett S, DeWyngaert K, Edmundson G . Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2001; 51(5):1422-30. DOI: 10.1016/s0360-3016(01)01616-9. View